Microwave Treatment of Common and Plantar Warts

Inclusion Criteria:

1. Provision of signed and dated informed consent form;
2. Stated willingness to comply with all study procedures and availability for the duration of the study;
3. Age 18-64 years inclusive;
4. A minimum of one clinically significant common wart (usually found on hands, knees and elbows), or one plantar wart. Note: the warts for treatment cannot be a mixture of common and plantar warts;
5. Subject's common warts must measure between 3mm-10mm or for plantar warts, measure between 3mm-20mm, inclusive;
6. If currently receiving treatment for common or plantar warts, agree to stop their current medication for at least 28 days prior to the start of study treatment;
7. Agrees to refrain from using any other wart removal products or treatments during the study period;
8. Agrees to not take any non-steroidal anti-inflammatory drugs (NSAIDs) or antihistamines within a 12-hour period prior to and after randomized treatment;
9. Able to perform study assessments.

Exclusion Criteria:

1. Pregnancy or breast feeding;
2. Mosaic warts for treatment;
3. Warts (common or plantar) that have been reported by the subject as present for more than 5 years (relates to any wart present and which may not necessarily be treated in this study);
4. Warts for treatment on areas of thin or sensitive skin as determined by the Investigator, e.g., face, neck, armpits, breasts, buttocks or genitals;
5. Areas for treatment where the skin is irritated, reddened or showing any sign of inflammation (e.g. itching and swelling);
6. Warts for treatment with hair growth, birthmarks, dark moles, pigmented skin or any other unusual skin condition;
7. History of infection in designated treatment area within 90 days prior to first treatment;
8. Implantable Cardioverter Defibrillator (ICD), pacemaker or other implantable electronic devices;
9. Metal implants at site of treatment (within foot or ankle);
10. Known allergy or intolerance to microwave therapy and cryotherapy;
11. Unstable co-morbidities (cardiovascular disease, active malignancy, inflammatory arthritis);
12. Participating in another interventional study or have done so within the last 30-days;
13. Anticipated relocation or extensive travel outside of the local study area preventing compliance with study procedures;
14. Circulatory conditions affecting the acral areas - peripheral vascular disease, peripheral ischemia, vasculitis, Raynaud's, or related conditions;
15. Peripheral neuropathy;
16. Subject with known immunosuppression disorders through illness or medication (for example - corticosteroids, biologic agents, methotrexate, ciclosporin);
17. Subject with autoimmune disease;
18. Diabetes (Type I or II);
19. History of vascular interventions to the legs, deemed as an unacceptable risk by the Investigator;
20. Prior dissection of axillary lymph nodes (for treated hand) or inguinal lymph nodes (for treated feet);
21. Dependent lymphedema;
22. Congestive heart failure;
23. History of repeated cellulitis (2 or more episodes);
24. History of deep venous thrombosis;
25. Subject currently receiving prescribed blood thinning medication;
26. Subject who has ever had any topical metallic treatment (e.g, aluminum chloride, silver nitrate) within the past year.